Ramucirumab in elderly patients with hepatocellular carcinoma and elevated alpha‐fetoprotein after sorafenib in REACH and REACH‐2

Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial

(2019) Andrew X Zhu et al.   LANCET ONCOLOGY

Management of adverse events associated with tyrosine kinase inhibitors: Improving outcomes for patients with hepatocellular carcinoma

(2019) Lorenza Rimassa et al.   CANCER TREATMENT REVIEWS

Outcomes and Quality of Life of Systemic Therapy in Advanced Hepatocellular Carcinoma

(2019) Kehua Zhou et al.   Cancers

758PRamucirumab in patients with advanced hepatocellular carcinoma (HCC) and elevated alpha fetoprotein (AFP): An exposure-response analysis

(2019) J Llovet et al.   ANNALS OF ONCOLOGY

LBA38_PRCheckMate 459: A randomized, multi-center phase III study of nivolumab (NIVO) vs sorafenib (SOR) as first-line (1L) treatment in patients (pts) with advanced hepatocellular carcinoma (aHCC)

(2019) T Yau et al.   ANNALS OF ONCOLOGY

Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial

(2019) Richard S. Finn et al.   JOURNAL OF CLINICAL ONCOLOGY

Diagnosis, Staging and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases

(2018) Jorge A. Marrero et al.   HEPATOLOGY

Age does not influence efficacy of ramucirumab in advanced gastric cancer: Subgroup analyses of REGARD and RAINBOW

(2018) Kei Muro et al.   JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY

EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma

(2018) Peter R. Galle et al.   JOURNAL OF HEPATOLOGY

Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial

(2018) Masatoshi Kudo et al.   LANCET

Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma

(2018) Ghassan K. Abou-Alfa et al.   NEW ENGLAND JOURNAL OF MEDICINE

OUP accepted manuscript

(2018)   ANNALS OF ONCOLOGY

Outcomes based on age in the phase 3 CELESTIAL trial of cabozantinib (C) versus placebo (P) in patients (pts) with advanced hepatocellular carcinoma (HCC).

(2018) Lorenza Rimassa et al.   JOURNAL OF CLINICAL ONCOLOGY

Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial

(2017) Jordi Bruix et al.   LANCET

Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial

(2015) Andrew X Zhu et al.   LANCET ONCOLOGY

Treatment for Hepatocellular Carcinoma in Elderly Patients: A Literature Review

(2013) Hiroki Nishikawa et al.   Journal of Cancer

EORTC elderly task force position paper: Approach to the older cancer patient

(2010) A.G. Pallis et al.   EUROPEAN JOURNAL OF CANCER